KR920703639A - 항-바이러스제와 이뮤노겐으로 유용하게 사용되는 비-복제성 리콤비넌트 레트로바이러스 물질 - Google Patents
항-바이러스제와 이뮤노겐으로 유용하게 사용되는 비-복제성 리콤비넌트 레트로바이러스 물질Info
- Publication number
- KR920703639A KR920703639A KR1019920701189A KR920701189A KR920703639A KR 920703639 A KR920703639 A KR 920703639A KR 1019920701189 A KR1019920701189 A KR 1019920701189A KR 920701189 A KR920701189 A KR 920701189A KR 920703639 A KR920703639 A KR 920703639A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- replicating
- recomponent
- gene
- host cell
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title claims description 10
- 239000003443 antiviral agent Substances 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 title description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 50
- 239000000463 material Substances 0.000 claims description 35
- 101710091045 Envelope protein Proteins 0.000 claims description 28
- 101710188315 Protein X Proteins 0.000 claims description 28
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 17
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 4
- 229940124551 recombinant vaccine Drugs 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims 67
- 238000000034 method Methods 0.000 claims 42
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims 29
- 239000002245 particle Substances 0.000 claims 29
- 108700004025 env Genes Proteins 0.000 claims 24
- 101150030339 env gene Proteins 0.000 claims 24
- 208000031886 HIV Infections Diseases 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 238000012258 culturing Methods 0.000 claims 16
- 239000001963 growth medium Substances 0.000 claims 15
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 14
- 238000004519 manufacturing process Methods 0.000 claims 14
- 102000011931 Nucleoproteins Human genes 0.000 claims 13
- 108010061100 Nucleoproteins Proteins 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- 108700004026 gag Genes Proteins 0.000 claims 11
- 101150098622 gag gene Proteins 0.000 claims 11
- 239000013612 plasmid Substances 0.000 claims 11
- 241001430294 unidentified retrovirus Species 0.000 claims 9
- 108010010369 HIV Protease Proteins 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 8
- 108091005804 Peptidases Proteins 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 102000007999 Nuclear Proteins Human genes 0.000 claims 6
- 108010089610 Nuclear Proteins Proteins 0.000 claims 6
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 238000005215 recombination Methods 0.000 claims 4
- 230000006798 recombination Effects 0.000 claims 4
- 108700004030 rev Genes Proteins 0.000 claims 4
- 101150098213 rev gene Proteins 0.000 claims 4
- 108700026220 vif Genes Proteins 0.000 claims 4
- 101150059019 vif gene Proteins 0.000 claims 4
- 108700026215 vpr Genes Proteins 0.000 claims 4
- 101150024249 vpr gene Proteins 0.000 claims 4
- 108700026222 vpu Genes Proteins 0.000 claims 4
- 101150090490 vpu gene Proteins 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 108010016191 Human immunodeficiency virus 2 p16 protease Proteins 0.000 claims 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 2
- 101710149951 Protein Tat Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101710200158 DNA packaging protein Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 101710160913 GemA protein Proteins 0.000 claims 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 210000004970 cd4 cell Anatomy 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 108700004027 tat Genes Proteins 0.000 claims 1
- 101150098170 tat gene Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 | |
| US439,205 | 1989-11-20 | ||
| PCT/US1990/006798 WO1991007425A1 (en) | 1989-11-20 | 1990-11-20 | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920703639A true KR920703639A (ko) | 1992-12-18 |
Family
ID=23743729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920701189A KR920703639A (ko) | 1989-11-20 | 1990-11-20 | 항-바이러스제와 이뮤노겐으로 유용하게 사용되는 비-복제성 리콤비넌트 레트로바이러스 물질 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0502105A4 (fi) |
| JP (1) | JPH05503629A (fi) |
| KR (1) | KR920703639A (fi) |
| AU (1) | AU636944B2 (fi) |
| CA (1) | CA2068713A1 (fi) |
| ES (1) | ES2052478T1 (fi) |
| FI (1) | FI922277A0 (fi) |
| GR (1) | GR930300005T1 (fi) |
| HU (1) | HUT60506A (fi) |
| NO (1) | NO921969L (fi) |
| OA (1) | OA09698A (fi) |
| TW (1) | TW216446B (fi) |
| WO (1) | WO1991007425A1 (fi) |
| ZA (1) | ZA909302B (fi) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0431128B1 (en) * | 1989-06-01 | 2003-03-26 | Applied Biotechnology, Inc. | Vector coding for self-assembled, defective, non-self-propagating viral particles |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| DE4124817A1 (de) * | 1991-07-26 | 1993-01-28 | Basf Ag | Waessrige polymerisatdispersionen |
| DE69232650T2 (de) * | 1991-11-08 | 2002-11-28 | Pharmacia & Upjohn Co., Kalamazoo | Vakzine gegen katzenleukämievirus |
| JPH07505412A (ja) * | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Ｃｔｌ応答の誘導 |
| EP1473369B1 (en) | 1993-01-26 | 2009-01-07 | The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) | Compositions and methods for delivery of genetic material |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| AU675702B2 (en) | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
| GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
| US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
| US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| EP0817854A2 (en) * | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| PT1141315E (pt) | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
| US20020106798A1 (en) | 2000-03-02 | 2002-08-08 | Robinson Harriet L. | DNA expression vectors and methods of use |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| CA2454959C (en) | 2001-03-08 | 2018-07-10 | Bernard Moss | Mva expressing modified hiv envelope, gag, and pol genes |
| CA2634992C (en) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AP2013007166A0 (en) | 2011-04-06 | 2013-10-31 | Univ Paris Descartes Inst De Rech Pour Le Dev Ird | Pharmaceutical compositions for preventing and/or treating an HIV disease in humans |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2020190750A1 (en) * | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| JPH02203783A (ja) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞 |
| JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| JPH05501201A (ja) * | 1989-10-16 | 1993-03-11 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 非感染性ｈｉｖ―１粒子およびそれらの使用 |
-
1990
- 1990-11-20 CA CA002068713A patent/CA2068713A1/en not_active Abandoned
- 1990-11-20 AU AU69055/91A patent/AU636944B2/en not_active Ceased
- 1990-11-20 ES ES91900526T patent/ES2052478T1/es active Pending
- 1990-11-20 JP JP3501082A patent/JPH05503629A/ja active Pending
- 1990-11-20 EP EP19910900526 patent/EP0502105A4/en not_active Withdrawn
- 1990-11-20 KR KR1019920701189A patent/KR920703639A/ko not_active Application Discontinuation
- 1990-11-20 ZA ZA909302A patent/ZA909302B/xx unknown
- 1990-11-20 WO PCT/US1990/006798 patent/WO1991007425A1/en not_active Application Discontinuation
- 1990-11-20 HU HU9201659A patent/HUT60506A/hu unknown
-
1991
- 1991-01-12 TW TW080100246A patent/TW216446B/zh active
-
1992
- 1992-05-19 FI FI922277A patent/FI922277A0/fi not_active Application Discontinuation
- 1992-05-19 NO NO92921969A patent/NO921969L/no unknown
- 1992-05-19 OA OA60209A patent/OA09698A/en unknown
-
1993
- 1993-04-28 GR GR930300005T patent/GR930300005T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI922277A (fi) | 1992-05-19 |
| JPH05503629A (ja) | 1993-06-17 |
| CA2068713A1 (en) | 1991-05-21 |
| EP0502105A4 (en) | 1993-02-24 |
| OA09698A (en) | 1993-08-30 |
| EP0502105A1 (en) | 1992-09-09 |
| FI922277A0 (fi) | 1992-05-19 |
| WO1991007425A1 (en) | 1991-05-30 |
| AU636944B2 (en) | 1993-05-13 |
| AU6905591A (en) | 1991-06-13 |
| HU9201659D0 (en) | 1992-08-28 |
| GR930300005T1 (fi) | 1993-04-28 |
| NO921969D0 (no) | 1992-05-19 |
| TW216446B (fi) | 1993-11-21 |
| ES2052478T1 (es) | 1994-07-16 |
| NO921969L (no) | 1992-06-26 |
| HUT60506A (en) | 1992-09-28 |
| ZA909302B (en) | 1991-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920703639A (ko) | 항-바이러스제와 이뮤노겐으로 유용하게 사용되는 비-복제성 리콤비넌트 레트로바이러스 물질 | |
| Mammano et al. | Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis | |
| Westervelt et al. | Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | |
| Young et al. | Virus-like particles: designing an effective AIDS vaccine | |
| Haffar et al. | Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system | |
| Kondo et al. | The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles | |
| Terwilliger et al. | Functional role of human immunodeficiency virus type 1 vpu. | |
| Earl et al. | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses | |
| Kleny et al. | Improved antigenicity of the HIV env protein by cleavage site removal | |
| EP1078105B1 (en) | Replication defective hiv vaccine | |
| Buonaguro et al. | Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A | |
| Barrett et al. | Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity | |
| Lu et al. | Utility of SHIV for testing HIV-1 vaccine candidates in macaques | |
| Carroll et al. | A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines | |
| McGettigan et al. | Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector | |
| Smith et al. | Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques | |
| Biggar et al. | Genetic variants of human T-lymphotropic virus type II in American Indian groups | |
| Verrier et al. | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates | |
| Hourioux et al. | Identification of the Glycoprotein 41™ Cytoplasmic Tail Domains of Human Immunodeficiency Virus Type 1 That Interact with Pr55Gag Particles | |
| Young et al. | Particle-based vaccines for HIV-1 infection | |
| Salemi et al. | The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy | |
| REITZ Jr et al. | Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV type IIIB) | |
| Girard et al. | Progress in the development of HIV vaccines | |
| Liska et al. | Localization of viral protein X in simian immunodeficiency virus macaque strain and analysis of its packaging requirements | |
| Shiraishi et al. | Myristoylation of human immunodeficiency virus type 1 gag protein is required for efficient env protein transportation to the surface of cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |